A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer

Matin, Farhana; Jeet, Varinder; Moya, Leire; Selth, Luke A.; Chambers, Suzanne K.; Yeadon, Trina; Saunders, Philippa; Eckert, Anne; Heathcote, Peter; Wood, Geoffrey A.; Malone, Greg; Samaratunga, Hemamali; Collins, Anne T.; Turner, Michelle; Kerr, Kathleen F.; Clements, Judith A.; Batra, Jyotsna

doi:10.1038/s41598-018-24424-w

Cited by 74 publications

(60 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Binary logistic regression was used to create the prediction model for combining the diagnostic effects of multiple miRNAs together. The P value 34 was calculated for each statistical analysis to indicate whether the null hypothesis can be refuted. 33…”

Section: Discussionmentioning

confidence: 99%

The MiR-17-92 Gene Cluster is a Blood-Based Marker for Cancer Detection in Non-Small-Cell Lung Cancer

Yang

Jia

Zhou

et al. 2020

The American Journal of the Medical Sciences

View full text Add to dashboard Cite

Background: Lung cancer is one of the most malignant cancers threatening human health. The miR-17-92 gene cluster is a highly conserved oncogene cluster encoding 6 miRNAs: miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a and miR-92a. This study explored whether these miRNAs can be used as diagnostic markers for non-small-cell lung cancer (NSCLC). Methods: Serum samples were collected from healthy subjects (n = 23) and NSCLC patients at various stages (n = 74). Serum RNA was extracted by the TRIzol-glycogen method, and cDNA libraries were constructed by reverse transcription. Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to detect the expression levels of the 6 miRNAs. Results: The expression levels of the 6 miRNAs varied in different stages of NSCLC. Thus, 2 receiver operating characteristic (ROC) curves, that is, normal subjects and stage I-III patients and normal subjects and stage IV patients, of each miRNA were established to determine the interval of normal DCt values. The 2 areas under the curve (AUCs) of each miRNA were investigated (miR-17: 0.8097 and 1.000; miR-18a: 0.7388 and 0.9907; miR-19a/19b: 0.8451 and 0.5104; miR-20a: 0.8975 and 1.000; miR-92a: 0.8097 and 0.8342). In addition, a high positive correlation was discovered between miR-17 and miR-20a expression. Combining these 2 miRNAs can improve the screening effect of NSCLC. Conclusion: The miR-17-92 gene cluster can likely serve as a diagnostic marker in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

The MiR-17-92 Gene Cluster is a Blood-Based Marker for Cancer Detection in Non-Small-Cell Lung Cancer

Yang

Jia

Zhou

et al. 2020

The American Journal of the Medical Sciences

View full text Add to dashboard Cite

show abstract

“…In another study, Matin at al. [128] discovered a four-miRNA panel (miR-98-5p, miR-152-3p, miR-326, and miR-4289) with increased levels in plasma samples from PC patients compared to healthy controls. Mahn et al [129] demonstrated that plasma miR-26a levels allowed discriminating between localized PC from benign prostate hyperplasia.…”

Section: Prostate Cancermentioning

confidence: 99%

The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies

Quirico¹,

Orso²

2020

CDR

View full text Add to dashboard Cite

In the last decades, progresses in medical oncology have ameliorated the treatment of patients and their outcome. However, further improvements are still necessary, in particular for certain types of tumors such as pancreatic, gastric, and lung cancer as well as acute myeloid leukemia where early detection and monitoring of the disease are crucial for final patient outcome. Liquid biopsy represents a great advance in the field because it is less invasive, less time-consuming, and safer compared to classical biopsies and it can be useful to monitor the evolution of the disease as well as the response of patients to therapy. Liquid biopsy allows the detection of circulating tumor cells, nucleic acids, and exosomes not only in blood but also in different biological fluids: urine, saliva, pleural effusions, cerebrospinal fluid, and stool. Among the potential biomarkers detectable in liquid biopsies, microRNAs (miRNAs) are gaining more and more attention, since they are easily detectable, quite stable in biological fluids, and show high sensitivity. Many data demonstrate that miRNAs alone or in combination with other biomarkers could improve the diagnostic and prognostic power for many different tumors. Despite this, standardization of methods, sample preparation, and analysis remain challenging and a huge effort should be made to address these issues before miRNA biomarkers can enter the clinic. This review summarizes the main findings in the field of circulating miRNAs in both solid and hematological tumors. MIRNAS AS POTENTIAL BIOMARKERSRecently, biomarker research has focused on RNA molecules circulating in the body fluids. RNA analysis is highly sensitive and specific, cheaper than protein analysis, and offers a more dynamic view of cell regulation and states compared to DNA [9] . Long RNA species, however, can be easily degraded by RNAse activity, while shorter RNA molecules, as small non-coding RNAs, are more stable and highly expressed in the blood of cancer patients [10,11] . miRNAs are small non-coding RNAs (19-22 nucleotides) originally discovered in Caenorhabditis elegans in 1993 [12] . In the last decades, miRNAs have been described in all animal models, and some of them resulted

show abstract

“…This microRNA is usually found down-regulated in prostate tumor tissues [100]. On the other hand, another member of the miR-98 family, miR-98-5p, was recently recognized as an important candidate in early diagnosis of prostate cancer from plasma samples together with miR-4289, miR-326 and miR-152-3p [76,101]. The encouraging results on miRNAs are becoming palpable rapidly in the context of precision medicine.…”

Section: Mirnas Therapeutic Role In Prostate Cancermentioning

confidence: 99%

MiRNA-Based Inspired Approach in Diagnosis of Prostate Cancer

Munteanu

Onaciu

et al. 2020

Medicina

View full text Add to dashboard Cite

Prostate cancer is one of the most encountered cancer diseases in men worldwide and in consequence it requires the improvement of therapeutic strategies. For the clinical diagnosis, the standard approach is represented by solid biopsy. From a surgical point of view, this technique represents an invasive procedure that may imply several postoperative complications. To overcome these impediments, many trends are focusing on developing liquid biopsy assays and on implementing them in clinical practice. Liquid samples (blood, urine) are rich in analytes, especially in transcriptomic information provided by genetic markers. Additionally, molecular characterization regarding microRNAs content reveals outstanding prospects in understanding cancer progression mechanisms. Moreover, these analytes have great potential for prostate cancer early detection, more accurate prostate cancer staging and also for decision making respecting therapy schemes. However, there are still questionable topics and more research is needed to standardize liquid biopsy-based techniques.

show abstract

A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer

Cited by 74 publications

References 74 publications

The MiR-17-92 Gene Cluster is a Blood-Based Marker for Cancer Detection in Non-Small-Cell Lung Cancer

The MiR-17-92 Gene Cluster is a Blood-Based Marker for Cancer Detection in Non-Small-Cell Lung Cancer

The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies

MiRNA-Based Inspired Approach in Diagnosis of Prostate Cancer

Contact Info

Product

Resources

About